Pre-made Tepoditamab benchmark antibody ( Bispecific mAb, anti-CLEC12A/CD371;CD3E therapeutic antibody, Anti-CLL-1/CLL1/DCAL-2/MICL;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-563

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-563 Category Tags ,

Product Details

Pre-Made Tepoditamab biosimilar, Bispecific mAb, Anti-CLEC12A/CD371;CD3E Antibody: Anti-CLL-1/CLL1/DCAL-2/MICL;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tepoditamab (formerly MCLA 117) a bispecific, human IgG antibody (with a silenced region), is being developed by Merus for the treatment of acute myeloid.

Products Name (INN Index)

Pre-Made Tepoditamab biosimilar, Bispecific mAb, Anti-CLEC12A/CD371;CD3E Antibody: Anti-CLL-1/CLL1/DCAL-2/MICL;T3E/TCRE/IMD18 therapeutic antibody

INN Name

Tepoditamab

Target

CLEC12A,CD3E

Format

Bispecific mAb

Derivation

Bispecific antibody

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa,Kappa

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Discontinued

100% SI Structure

None;None

99% SI Structure

None;None

95-98% SI Structure

None;None

Year Proposed

2017

Companies

Genmab,Janssen Research & Development

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Acute myeloid leukaemia,Myelodysplastic syndromes

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

CLEC12A,CD3E

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide